Novavax's experimental COVID-19-influenza combination and standalone influenza vaccines generated a strong immune response in ...

US biotech Novavax (Nasdaq: NVAX) has reported that its experimental combination COVID-19 and influenza vaccine generated ...

Goldman Sachs 46th Annual Global Healthcare Conference June 11, 2025 2:00 PM ETCompany ParticipantsJames Patrick Kelly ...

Novavax (NasdaqGS:NVAX) recently reported initial results from its Phase 3 trial for its COVID-19-Influenza Combination and seasonal influenza vaccines, which showed immune responses comparable to ...

Novavax's combo and standalone flu vaccines showed strong immune responses and good safety in a Phase 3 trial of adults 65 ...

The Gaithersburg, Md., biotechnology company said Wednesday that results of the initial cohort of vaccines showed both the Covid-19-influenza combination and flu-vaccine candidates induced immune ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Novavax, Inc. (NVAX) on Wednesday said that its COVID-19-Influenza combination and stand-alone Influenza vaccine candidates ...

Novavax (NVAX) stock gains as the company reports promising Phase 3 trial results for its COVID-19-Influenza combo vaccine and stand-alone flu shot. Read more here.

COVID-19-influenza combination (CIC) and stand-alone trivalent hemagglutinin nanoparticle seasonal influenza (TNIV) phase 3 ...

Victoria’s Secret (NYSE: VSCO) stock rose 0.4% after the lingerie retailer, reaffirmed its full-year sales guidance and ...